News

GSK Seeks FDA Nod To Broaden RSV Vaccine For Younger At-Risk Adults
FDA accepts GSK's application to expand Arexvy vaccine use to at-risk adults aged 18–49, with a decision expected in the ...
Pharmabiz6h
GSK announces US FDA accepts application to review expanded use of RSV vaccine, Arexvy for adults 18-49 at increased risk
GSK announces US FDA accepts application to review expanded use of RSV vaccine, Arexvy for adults 18-49 at increased risk: London, UK Wednesday, July 16, 2025, 14:00 Hrs [IST] GSK ...
MPR20h
FDA to Review Arexvy for 18 to 49-Year-Olds at Increased RSV Disease Risk
Arexvy is currently approved to prevent lower respiratory tract disease (LRTD) caused by RSV in individuals aged 60 years and older, and those 50 to 59 years of age who are at increased risk for LRTD ...
The FTSE 100 sits at a record high. But some stocks still look dirt cheap!
The usually sluggish FTSE 100 is having a surprisingly good year. But our writer feels there are still potential bargains ...
Fierce Pharma19h
Regulatory tracker: Vertex, NHS England reach reimbursement deal for CF drug Alyftrek
Welcome to Fierce Pharma's regulatory tracker for the second half of 2025. | In this tracker, Fierce Pharma is recording the ...